Neuropathix, Inc
Neuropathix, Inc. is a pioneering biopharmaceutical company advancing globally patented, synthetic cannabinoid-inspired therapeutics for the treatment of neurodegenerative and neuropathic diseases. Headquartered at the Pennsylvania Biotechnology Center with its wholly owned subsidiary Kannalife Sciences, Inc, it’s lead drug candidate, KLS-13019, targets key drivers of neuroinflammation and mitochondrial dysfunction, including mNCX-1, GPR55, and the NLRP3 inflammasome. The company’s innovation has been recognized through substantial non-dilutive funding, including a $1.5 million grant from The Michael J. Fox Foundation for Parkinson’s Research and $3.3 million from the NIH HEAL Initiative to support IND-enabling studies to advance KLS-13019 toward clinical trials.
7-day free trial · no credit card
Verified contacts
3
available on Kipplo
LinkedIn employees
3
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 3 verified contacts at Neuropathix, Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
3 contacts with verified email or phone · masked until revealed.
Showing 1 of 3 verified contacts
Top roles at Neuropathix, Inc
2 distinct titles indexed · top 2 shown.
- 2chief executive officer
- 1chairman of scientific advisory board board member
Sign up to unlock all 3 contacts at Neuropathix, Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 3 verified contacts at Neuropathix, Inc
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.